Skip to main content
. 2022 Nov 7;80(20):1900–1908. doi: 10.1016/j.jacc.2022.08.799

Figure 1.

Figure 1

Myocarditis Study Population and Participant Enrollment Flowchart

Individuals aged ≥18 years with a record of a second messenger RNA (mRNA) vaccination dose (BNT162b2 or mRNA-1273) following receipt of the first dose of an mRNA vaccine in the Provincial Immunization Registry (PIR) between January 1, 2021, and September 9, 2021, were eligible for participation. Individuals with any vaccine dose administered outside of British Columbia (BC) and with a history of myocarditis within 1 year before the second dose were excluded. An occurrence of myocarditis within 7 and 21 days after second dose of vaccine was recorded as an event.